{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:59:49Z","timestamp":1793674789164,"version":"4.5.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41591-019-0344-3","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T17:04:30Z","timestamp":1550509470000},"page":"427-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":429,"title":["Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy"],"prefix":"10.1038","volume":"25","author":[{"given":"Christopher E.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Gemberling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel D.","family":"Bohning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline N.","family":"Robinson-Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bulaklak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth M.","family":"Castellanos Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel H.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Asokan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-4013","authenticated-orcid":false,"given":"Charles A.","family":"Gersbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"344_CR1","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2017.126","volume":"13","author":"CE Nelson","year":"2017","unstructured":"Nelson, C. E., Robinson-Hamm, J. N. & Gersbach, C. A. Genome engineering: a new approach to gene therapy for neuromuscular disorders. Nat. Rev. Neurol. 13, 647\u2013661 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"344_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/mt.2015.192","volume":"24","author":"L Xu","year":"2016","unstructured":"Xu, L. et al. CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol. Ther. 24, 564\u2013569 (2016).","journal-title":"Mol. Ther."},{"key":"344_CR3","doi-asserted-by":"crossref","unstructured":"Long, C., Amoasii, L., Bassel-Duby, R. & Olson, E. N. Genome editing of monogenic neuromuscular diseases: a systematic review. JAMA Neurol. 73, 1349\u20131355 (2016).","DOI":"10.1001\/jamaneurol.2016.3388"},{"key":"344_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403\u2013407 (2016).","journal-title":"Science"},{"key":"344_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407\u2013411 (2016).","journal-title":"Science"},{"key":"344_CR6","doi-asserted-by":"publisher","first-page":"14454","DOI":"10.1038\/ncomms14454","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson, N. E. et al. Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat. Commun. 8, 14454 (2017).","journal-title":"Nat. Commun."},{"key":"344_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nmeth.3993","volume":"13","author":"WL Chew","year":"2016","unstructured":"Chew, W. L. et al. A multifunctional AAV-CRISPR\u2013Cas9 and its host response. Nat. Methods 13, 868\u2013874 (2016).","journal-title":"Nat. Methods"},{"key":"344_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","volume":"32","author":"KM Flanigan","year":"2014","unstructured":"Flanigan, K. M. Duchenne and Becker muscular dystrophies. Neurol. Clin. 32, 671\u2013688 (2014).","journal-title":"Neurol. Clin."},{"key":"344_CR9","doi-asserted-by":"crossref","unstructured":"Hoffman, E. P., Brown, R. H. Jr. & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919\u2013928 (1987).","DOI":"10.1016\/0092-8674(87)90579-4"},{"key":"344_CR10","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","volume":"25","author":"JR Chamberlain","year":"2017","unstructured":"Chamberlain, J. R. & Chamberlain, J. S. Progress toward gene therapy for Duchenne muscular dystrophy. Mol. Ther. 25, 1125\u20131131 (2017).","journal-title":"Mol. Ther."},{"key":"344_CR11","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00439-016-1725-z","volume":"135","author":"JN Robinson-Hamm","year":"2016","unstructured":"Robinson-Hamm, J. N. & Gersbach, C. A. Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy. Hum. Genet. 135, 1029\u20131040 (2016).","journal-title":"Hum. Genet."},{"key":"344_CR12","doi-asserted-by":"crossref","unstructured":"Dunbar, C. E. et al. Gene therapy comes of age. Science 359, eaan4672 (2018).","DOI":"10.1126\/science.aan4672"},{"key":"344_CR13","doi-asserted-by":"crossref","unstructured":"Sharma, R. et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 126, 1777\u20131784 (2015).","DOI":"10.1182\/blood-2014-12-615492"},{"key":"344_CR14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.ymthe.2018.03.002","volume":"26","author":"K Laoharawee","year":"2018","unstructured":"Laoharawee, K. et al. Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing. Mol. Ther. 26, 1127\u20131136 (2018).","journal-title":"Mol. Ther."},{"key":"344_CR15","unstructured":"Amoasii, L. et al. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci. Transl. Med. 9, eaan8081 (2017)."},{"key":"344_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii, L. et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 362, 86\u201391 (2018).","journal-title":"Science"},{"key":"344_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186\u2013191 (2015).","journal-title":"Nature"},{"key":"344_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","volume":"15","author":"MA Kotterman","year":"2014","unstructured":"Kotterman, M. A. & Schaffer, D. V. Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet. 15, 445\u2013451 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"344_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1006\/clim.2000.4966","volume":"98","author":"MJ Spencer","year":"2001","unstructured":"Spencer, M. J., Montecino-Rodriguez, E., Dorshkind, K. & Tidball, J. G. Helper (CD4+) and cytotoxic (CD8+) T cells promote the pathology of dystrophin-deficient muscle. Clin. Immunol. 98, 235\u2013243 (2001).","journal-title":"Clin. Immunol."},{"key":"344_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","volume":"17","author":"MA Kotterman","year":"2015","unstructured":"Kotterman, M. A., Chalberg, T. W. & Schaffer, D. V. Viral vectors for gene therapy: translational and clinical outlook. Annu. Rev. Biomed. Eng. 17, 63\u201389 (2015).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"344_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/jgm.516","volume":"6","author":"AR Brooks","year":"2004","unstructured":"Brooks, A. R. et al. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J. Gene Med. 6, 395\u2013404 (2004).","journal-title":"J. Gene Med."},{"key":"344_CR22","doi-asserted-by":"publisher","unstructured":"Charlesworth, C. T. et al. Identification of pre-existing adaptive immunity to Cas9 Proteins in humans. Nat. Med. \n                    https:\/\/doi.org\/10.1038\/s41591-018-0326-x\n                    \n                   (2019).","DOI":"10.1038\/s41591-018-0326-x"},{"key":"344_CR23","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41467-018-04048-4","volume":"9","author":"PI Thakore","year":"2018","unstructured":"Thakore, P. I. et al. RNA-guided transcriptional silencing in vivo with S. aureus CRISPR\u2013Cas9 repressors. Nat. Commun. 9, 1674 (2018).","journal-title":"Nat. Commun."},{"key":"344_CR24","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/gt.2011.200","volume":"19","author":"C Hu","year":"2012","unstructured":"Hu, C. & Lipshutz, G. S. AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice. Gene Ther. 19, 1166\u20131176 (2012).","journal-title":"Gene Ther."},{"key":"344_CR25","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1038\/mt.2012.129","volume":"20","author":"EK Lee","year":"2012","unstructured":"Lee, E. K. et al. Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy. Mol. Ther. 20, 1844\u20131851 (2012).","journal-title":"Mol. Ther."},{"key":"344_CR26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.ymthe.2018.02.023","volume":"26","author":"K Singh","year":"2018","unstructured":"Singh, K. et al. Efficient in vivo liver-directed gene editing using CRISPR\/Cas9. Mol. Ther. 26, 1241\u20131254 (2018).","journal-title":"Mol. Ther."},{"key":"344_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/hum.2011.063","volume":"23","author":"P Zhang","year":"2012","unstructured":"Zhang, P. et al. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease. Hum. Gene Ther. 23, 460\u2013472 (2012).","journal-title":"Hum. Gene Ther."},{"key":"344_CR28","doi-asserted-by":"crossref","unstructured":"Ferdosi, S. R. et al. Multifunctional CRISPR\/Cas9 with engineered immunosilenced human T cell epitopes. Preprint at \n                    https:\/\/www.biorxiv.org\/content\/early\/2018\/07\/02\/360198\n                    \n                   (2018).","DOI":"10.1101\/360198"},{"key":"344_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1146\/annurev-chembioeng-080615-034711","volume":"7","author":"CE Nelson","year":"2016","unstructured":"Nelson, C. E. & Gersbach, C. A. Engineering delivery vehicles for genome editing. Annu. Rev. Chem. Biomol. Eng. 7, 637\u2013662 (2016).","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"344_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12864-018-4561-9","volume":"19","author":"G Giannoukos","year":"2018","unstructured":"Giannoukos, G. et al. UDiTaSTM, a genome editing detection method for indels and genome rearrangements. BMC Genomics 19, 212 (2018).","journal-title":"BMC Genomics"},{"key":"344_CR31","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1038\/mtna.2015.58","volume":"5","author":"JP Iyombe-Engembe","year":"2016","unstructured":"Iyombe-Engembe, J. P. et al. Efficient restoration of the dystrophin gene reading frame and protein structure in DMD myoblasts using the CinDel method. Mol. Ther. Nucleic Acids 5, e283 (2016).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"344_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt0918-899c","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat. Biotechnol. 36, 765\u2013771 (2018).","journal-title":"Nat. Biotechnol."},{"key":"344_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature11928","volume":"495","author":"S Memczak","year":"2013","unstructured":"Memczak, S. et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333\u2013338 (2013).","journal-title":"Nature"},{"key":"344_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DB Cox","year":"2015","unstructured":"Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121\u2013131 (2015).","journal-title":"Nat. Med."},{"key":"344_CR35","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/ng1380","volume":"36","author":"DG Miller","year":"2004","unstructured":"Miller, D. G., Petek, L. M. & Russell, D. W. Adeno-associated virus vectors integrate at chromosome breakage sites. Nat. Genet. 36, 767\u2013773 (2004).","journal-title":"Nat. Genet."},{"key":"344_CR36","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/JCI79213","volume":"125","author":"RJ Chandler","year":"2015","unstructured":"Chandler, R. J. et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J. Clin. Invest. 125, 870\u2013880 (2015).","journal-title":"J. Clin. Invest."},{"key":"344_CR37","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature13864","volume":"517","author":"A Barzel","year":"2015","unstructured":"Barzel, A. et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature 517, 360\u2013364 (2015).","journal-title":"Nature"},{"key":"344_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ymthe.2005.03.020","volume":"12","author":"P Bell","year":"2005","unstructured":"Bell, P. et al. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol. Ther. 12, 299\u2013306 (2005).","journal-title":"Mol. Ther."},{"key":"344_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1126\/science.1142658","volume":"317","author":"A Donsante","year":"2007","unstructured":"Donsante, A. et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477 (2007).","journal-title":"Science"},{"key":"344_CR40","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/mt.2016.52","volume":"24","author":"I Gil-Farina","year":"2016","unstructured":"Gil-Farina, I. et al. Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol. Ther. 24, 1100\u20131105 (2016).","journal-title":"Mol. Ther."},{"key":"344_CR41","unstructured":"Gombash Lampe, S. E., Kaspar, B. K. & Foust, K. D. Intravenous injections in neonatal mice. J. Vis. Exp. 93, e52037 (2014)."},{"key":"344_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nbt.3583","volume":"34","author":"L Pinello","year":"2016","unstructured":"Pinello, L. et al. Analyzing CRISPR genome-editing experiments with CRISPResso. Nat. Biotechnol. 34, 695\u2013697 (2016).","journal-title":"Nat. Biotechnol."},{"key":"344_CR43","unstructured":"Wang, D. et al. Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum. Gene Ther. 26, 432\u2013442 (2015)."},{"key":"344_CR44","doi-asserted-by":"publisher","first-page":"8776","DOI":"10.1016\/j.biomaterials.2013.07.063","volume":"34","author":"J Chen","year":"2013","unstructured":"Chen, J. et al. The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials 34, 8776\u20138785 (2013).","journal-title":"Biomaterials"},{"key":"344_CR45","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli, C. et al. Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073\u20131080 (2008).","journal-title":"Mol. Ther."},{"key":"344_CR46","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gr.849004","volume":"14","author":"GE Crooks","year":"2004","unstructured":"Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188\u20131190 (2004).","journal-title":"Genome Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0344-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:58:36Z","timestamp":1684619916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-019-0344-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1038\/s41591-019-0344-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"7 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.N.R.-H., C.E.N. and C.A.G. have filed patent applications related to genome editing for Duchenne muscular dystrophy. C.A.G. is an advisor for Sarepta Therapeutics, and a co-founder of and advisor for Element Genomics and Locus Biosciences. A.A. is a co-founder of and advisor for StrideBio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}